Laronidase · ALDURAZYME
Protein / enzyme therapeutic
Evidence outlook
Approved: Mucopolysaccharidosis Type I
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
Also approved (2)
- MPS I
- Long-term enzyme replacement therapy in confirmed MPS I
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00741338 NCT00741338 · Mucopolysaccharidosis Type I The study was open-label and had no comparator arm, despite the registry also labeling the allocation as randomized, with only 7 enrolled participants. Its primary endpoint was an anti-laronidase antibody-titer measure rather than a clinical outcome, and the reported results were 0 of 3 versus 1 of 3 participants achieving immune tolerance, without a formal comparison. Registry: NCT00741338 | 1/2 | Number of Participants Who Achieved Immune Tolerance Induction (24 weeks after start of full-dose laronidase therapy) 2012-09 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
View 1 more trial
NCT00258011 NCT00258011 · Mucopolysaccharidosis Type I This was a single-arm, open-label study in only 3 patients with no control group and no blinding, so it cannot show whether the drug caused the observed changes. It was designed primarily to assess safety rather than to test efficacy. Registry: NCT00258011 | 3 | Safety Evaluation (Up to 73 Weeks) 2006-10 | Safety Evaluation (Up to 73 Weeks): Aldurazyme (Laronidase) Treatment — Having Adverse Events (AEs): 3 participants; Having drug related AEs: 0 participants; Discontinuations due to AEs: 0 participants; Having Serious AEs: 1 participants; Having Severe AEs: 1 participants; Deaths: 0 participants; Having infusion-associated reactions: 0 participants | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow ALDURAZYME (Laronidase) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.